MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318652 | Name: Ranolazine HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ranolazine is an anti-ischemic compound, which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Ranolazine HCl is a salt form of Ranolazine.

Chemical Structure

Ranolazine HCl
Ranolazine HCl
CAS# 95635-56-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 318652

Name: Ranolazine HCl

CAS#: 95635-56-6 (HCl)

Chemical Formula: C24H35Cl2N3O4

Exact Mass: 0.0000

Molecular Weight: 500.46

Elemental Analysis: C, 57.60; H, 7.05; Cl, 14.17; N, 8.40; O, 12.79

Price and Availability

Size Price Availability Quantity
1g USD 350.00 2 weeks
5g USD 950.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
95635-55-5 (free base) 95635-56-6 (HCl)
Synonym
RS 43285; RS-43285; RS43285; CVT-303; CVT 303; CVT303; Ranolazine; Ranexa; Latixa; Ranexa; Ranolazine Dihydrochloride; Ranolazine HCl; Ranolazine Hydrochloride.
IUPAC/Chemical Name
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride
InChi Key
RJNSNFZXAZXOFX-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H
SMILES Code
O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#95635-55-5 (Ranolazine free base). CAS# 95635-56-6 (Ranolazine HCl)
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ranolazine dihydrochloride is an antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late INa and IKr currents.
In vitro activity:
This study suggests that ranolazine could block multiple ion currents such as I(Na) and I(K(IR)) and suggests that these actions may contribute to some of the functional activities of neurons and endocrine or neuroendocrine cells in vivo. Reference: J Pharmacol Sci. 2009 Jul;110(3):295-305. https://pubmed.ncbi.nlm.nih.gov/19609066/
In vivo activity:
This study found that animals with hypothyroidism have increased susceptibility to developing arrhythmia.Ranolazine is able to correct the arrhythmic phenotype. Reference: Life Sci. 2022 Nov 1;308:120945. https://pubmed.ncbi.nlm.nih.gov/36096245/
Solvent mg/mL mM
Solubility
DMSO 20.0 39.96
DMF 20.0 39.96
Water 20.0 39.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 500.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. da Silva MV, Santos-Miranda A, Joviano-Santos JV, Souza DS, Marques LP, Sarmento JO, Beserra SS, Roman-Campos D. The insecticide β-Cyfluthrin induces acute arrhythmic cardiotoxicity through interaction with NaV1.5 and ranolazine reverses the phenotype. Clin Sci (Lond). 2022 Mar 18;136(5):329-343. doi: 10.1042/CS20211151. PMID: 35190819. 2. Chen BS, Lo YC, Peng H, Hsu TI, Wu SN. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells. J Pharmacol Sci. 2009 Jul;110(3):295-305. doi: 10.1254/jphs.09018fp. PMID: 19609066. 3. Han QJ, Forfia P, Vaidya A, Ramani G, deKemp RA, Mach RH, Mankoff DA, Bravo PE, DiCarli M, Chan SY, Waxman AB, Han Y. Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study. Front Cardiovasc Med. 2023 Jun 13;10:1118796. doi: 10.3389/fcvm.2023.1118796. PMID: 37383703; PMCID: PMC10293744. 4. Souza DS, Marques LP, Costa AD, Cruz JS, Rhana P, Santos-Miranda A, Joviano-Santos JV, Durço AO, Vasconcelos CML, Roman-Campos D. Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype. Life Sci. 2022 Nov 1;308:120945. doi: 10.1016/j.lfs.2022.120945. Epub 2022 Sep 9. PMID: 36096245.
In vitro protocol:
1. da Silva MV, Santos-Miranda A, Joviano-Santos JV, Souza DS, Marques LP, Sarmento JO, Beserra SS, Roman-Campos D. The insecticide β-Cyfluthrin induces acute arrhythmic cardiotoxicity through interaction with NaV1.5 and ranolazine reverses the phenotype. Clin Sci (Lond). 2022 Mar 18;136(5):329-343. doi: 10.1042/CS20211151. PMID: 35190819. 2. Chen BS, Lo YC, Peng H, Hsu TI, Wu SN. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells. J Pharmacol Sci. 2009 Jul;110(3):295-305. doi: 10.1254/jphs.09018fp. PMID: 19609066.
In vivo protocol:
1. Han QJ, Forfia P, Vaidya A, Ramani G, deKemp RA, Mach RH, Mankoff DA, Bravo PE, DiCarli M, Chan SY, Waxman AB, Han Y. Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study. Front Cardiovasc Med. 2023 Jun 13;10:1118796. doi: 10.3389/fcvm.2023.1118796. PMID: 37383703; PMCID: PMC10293744. 2. Souza DS, Marques LP, Costa AD, Cruz JS, Rhana P, Santos-Miranda A, Joviano-Santos JV, Durço AO, Vasconcelos CML, Roman-Campos D. Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype. Life Sci. 2022 Nov 1;308:120945. doi: 10.1016/j.lfs.2022.120945. Epub 2022 Sep 9. PMID: 36096245.
1: Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016 May;18(5):463-74. doi: 10.1111/dom.12629. Epub 2016 Feb 23. PubMed PMID: 26749407. 2: Hartmann N, Mason FE, Braun I, Pabel S, Voigt N, Schotola H, Fischer TH, Dobrev D, Danner BC, Renner A, Gummert J, Belardinelli L, Frey N, Maier LS, Hasenfuss G, Sossalla S. The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology. J Mol Cell Cardiol. 2016 Apr 4. pii: S0022-2828(16)30059-1. doi: 10.1016/j.yjmcc.2016.03.012. [Epub ahead of print] PubMed PMID: 27056421. 3: Cacciapuoti F. Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease. Ther Adv Cardiovasc Dis. 2016 Apr;10(2):98-102. doi: 10.1177/1753944716636042. Epub 2016 Mar 3. Review. PubMed PMID: 26944071. 4: Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Hirakawa R, Smith-Maxwell C, Wu L, Dhalla AK, Rajamani S, Mollova N, Stafford B, Tang J, Belardinelli L, Zablocki JA. Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I(Na)i) of the cardiac Na(v)1.5 channel with improved efficacy and potency relative to ranolazine. Bioorg Med Chem Lett. 2016 Mar 26. pii: S0960-894X(16)30328-6. doi: 10.1016/j.bmcl.2016.03.096. [Epub ahead of print] PubMed PMID: 27038498. 5: Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris. Int J Cardiol. 2016 Mar 2;211:105-111. doi: 10.1016/j.ijcard.2016.02.140. [Epub ahead of print] Review. PubMed PMID: 26994453. 6: Saad M, Mahmoud A, Elgendy IY, Richard Conti C. Ranolazine in Cardiac Arrhythmia. Clin Cardiol. 2016 Mar;39(3):170-8. doi: 10.1002/clc.22476. Epub 2015 Oct 13. Review. PubMed PMID: 26459200. 7: Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Notte GT, Kalla R, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Smith-Maxwell C, Dhalla AK, Rajamani S, Stafford B, Tang J, Mollova N, Belardinelli L, Zablocki JA. Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I(Na)i) of the cardiac Na(V) 1.5 channel with improved efficacy and potency relative to ranolazine. Bioorg Med Chem Lett. 2016 Mar 30. pii: S0960-894X(16)30331-6. doi: 10.1016/j.bmcl.2016.03.101. [Epub ahead of print] PubMed PMID: 27080178. 8: Lee JC, Kim KC, Choe SY, Hong YM. Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment. Anat Cell Biol. 2016 Mar;49(1):7-14. doi: 10.5115/acb.2016.49.1.7. Epub 2016 Mar 28. PubMed PMID: 27051563; PubMed Central PMCID: PMC4819080. 9: Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3). pii: e003196. doi: 10.1161/JAHA.116.003196. Review. PubMed PMID: 26979079. 10: Greiner L, Hurren K, Brenner M. Ranolazine and Its Effects on Hemoglobin A1C. Ann Pharmacother. 2016 Feb 25. pii: 1060028016631757. [Epub ahead of print] Review. PubMed PMID: 26917816. 11: Redfors B, Généreux P. Ranolazine following percutaneous coronary intervention: For whom? For what? Expert Rev Cardiovasc Ther. 2016 Feb 27:1-3. [Epub ahead of print] PubMed PMID: 26840661. 12: Alexopoulos D, Kochiadakis G, Afthonidis D, Barbetseas J, Kelembekoglou P, Limberi S, Spanos A, Triantafyllidis G. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR). Int J Cardiol. 2016 Feb 15;205:111-6. doi: 10.1016/j.ijcard.2015.10.180. Epub 2015 Oct 26. PubMed PMID: 26730841. 13: Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016 Jan 5;133(1):39-47. doi: 10.1161/CIRCULATIONAHA.115.019768. Epub 2015 Nov 10. PubMed PMID: 26555329. 14: Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S, Wagner S, Stathopoulou K, Söhren KD, Weinberger F, Schwedhelm E, Cuello F, Maier LS, Eschenhagen T, Carrier L. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovasc Res. 2016 Jan 1;109(1):90-102. doi: 10.1093/cvr/cvv247. Epub 2015 Nov 3. PubMed PMID: 26531128. 15: Aldasoro M, Guerra-Ojeda S, Aguirre-Rueda D, Mauricio MD, Vila JM, Marchio P, Iradi A, Aldasoro C, Jorda A, Obrador E, Valles SL. Effects of Ranolazine on Astrocytes and Neurons in Primary Culture. PLoS One. 2016 Mar 7;11(3):e0150619. doi: 10.1371/journal.pone.0150619. eCollection 2016. PubMed PMID: 26950436; PubMed Central PMCID: PMC4780741. 16: Mihos CG, Krishna RK, Kherada N, Larrauri-Reyes M, Tolentino A, Santana O. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. Pharmacol Res. 2016 Jan;103:49-55. doi: 10.1016/j.phrs.2015.10.018. Epub 2015 Nov 4. Review. PubMed PMID: 26546970. 17: Head SJ, Kappetein AP. Coronary artery disease: a dam in the river for ranolazine. Lancet. 2016 Jan 9;387(10014):100-2. doi: 10.1016/S0140-6736(15)00458-4. Epub 2015 Oct 22. PubMed PMID: 26474812. 18: Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. PubMed PMID: 26474810. 19: Calderón-Sánchez EM, Domínguez-Rodríguez A, López-Haldón J, Jiménez-Navarro MF, Gómez AM, Smani T, Ordóñez A. Cardioprotective Effect of Ranolazine in the Process of Ischemia-reperfusion in Adult Rat Cardiomyocytes. Rev Esp Cardiol (Engl Ed). 2016 Jan;69(1):45-53. doi: 10.1016/j.rec.2015.02.027. Epub 2015 Jul 14. PubMed PMID: 26183665. 20: Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study. BMC Health Serv Res. 2015 Dec 18;15:566. doi: 10.1186/s12913-015-1228-y. PubMed PMID: 26684327; PubMed Central PMCID: PMC4683812.